Thrivent Financial for Lutherans
BBH icon

Thrivent Financial for Lutherans’s VanEck Biotech ETF BBH Stock Holding History

Thrivent Financial for Lutherans’s Portfolio BBH Stock Details BBH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-120
Closed -$14K – 2029
2017
Q1 		$14K Hold
120
– – ﹤0.01% 1940
2016
Q4 		$14K Buy
+120
New +$13.1K ﹤0.01% 1929

Other funds holding BBH

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
MCM
Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
SFS
Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return
BRM
Boston Research & Management Manchester, Massachusetts $421M AUM 16.18% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
AL
Aspiriant LLC Los Angeles, California $4.05B AUM 19.01% 1-Year Est. Return

Thrivent Financial for Lutherans's BBH Position: Q2 2017 in Review

Thrivent Financial for Lutherans sold out of VanEck Biotech ETF (BBH) in Q2 2017, closing a stake of 120 shares — an estimated $14K sold.

Thrivent Financial for Lutherans first reported a position in BBH in Q4 2016 and held it in 2 quarters. The position peaked at $14K in Q1 2017. 83 funds tracked by Wall St. Rank hold BBH as of Q2 2017.

  • Thrivent Financial for Lutherans reported no remaining VanEck Biotech ETF position as of Q2 2017 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 120 VanEck Biotech ETF shares in Q2 2017, an estimated $14K.
  • Thrivent Financial for Lutherans first reported a position in VanEck Biotech ETF in Q4 2016 and held it in 2 quarters.
  • Thrivent Financial for Lutherans's VanEck Biotech ETF position peaked at $14K in Q1 2017.
  • 83 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2017.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2017, filed 11 Aug 2017.